Clinical trial registry record

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 6, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07330674
Last registry update
February 6, 2026
Status
Recruiting
Phase
Phase 1
Sponsor
Aptabio Therapeutics, Inc.
Enrollment
68
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
68
Population
ALL · 18 Years to 50 Years
Duration
2026-02-01 to 2027-12-01
Intervention
ABF-101; Placebo
Comparator
Not reported
Outcomes measured
Number of Participants with treatment-emergent adverse event — From enrollment up to 12 weeks; Maximum Observed Plasma Concentration (Cmax) of ABF-101 — From enrollment up to 12 weeks; Time to maximal concentration (Tmax) of ABF-101 — From enrollment up to 12 weeks; The plasma area under the curve (AUC) of ABF-101 — From enrollment up to 12 weeks; Terminal elimination half-life of ABF-101 — From enrollment up to 12 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON